[{"bbox": [674, 101, 838, 130], "category": "Page-header", "text": "2023年年度报告"}, {"bbox": [218, 183, 426, 217], "category": "Text", "text": "□适用 √不适用"}, {"bbox": [230, 256, 489, 289], "category": "Text", "text": "主要研发项目投入情况"}, {"bbox": [222, 298, 424, 329], "category": "Text", "text": "√适用 □不适用"}, {"bbox": [1014, 331, 1299, 361], "category": "Text", "text": "单位：元 币种：人民币"}, {"bbox": [205, 363, 1310, 656], "category": "Table", "text": "<table><thead><tr><th>研发项目</th><th>研发投入金额</th><th>研发投入费用化金额</th><th>研发投入资本化金额</th><th>研发投入占营业收入比例 (%)</th><th>本期金额较上年同期变动比例 (%)</th><th>情况说明</th></tr></thead><tbody><tr><td>抗糖尿病创新药</td><td>40,085,842.54</td><td>40,085,842.54</td><td></td><td>1.84</td><td>464.12</td><td></td></tr><tr><td>抗肿瘤创新药物</td><td>3,869,853.83</td><td>3,869,853.83</td><td></td><td>0.18</td><td>-70.93</td><td></td></tr><tr><td>赛洛多辛胶囊</td><td>3,701,635.79</td><td>3,701,635.79</td><td></td><td>0.17</td><td>31.76</td><td></td></tr><tr><td>LH-2218 的研究与开发</td><td>2,967,539.35</td><td>2,967,539.35</td><td></td><td>0.14</td><td></td><td></td></tr><tr><td>治疗 COPD 创新药物</td><td>2,887,913.69</td><td>2,887,913.69</td><td></td><td>0.13</td><td>-53.27</td><td></td></tr></tbody></table>"}, {"bbox": [216, 688, 1284, 759], "category": "Text", "text": "情况说明：报告期内，以上研发项目投入较同期变化较大，主要原因为项目所处研发阶段不同，所进行的试验项目内容不同。"}, {"bbox": [229, 805, 542, 837], "category": "Section-header", "text": "### 3. 公司药（产）品销售情况"}, {"bbox": [233, 845, 490, 877], "category": "Section-header", "text": "#### (1). 主要销售模式分析"}, {"bbox": [222, 886, 424, 917], "category": "Text", "text": "√适用 □不适用"}, {"bbox": [268, 920, 465, 951], "category": "Section-header", "text": "##### 1、制剂产品销售"}, {"bbox": [216, 956, 1297, 1026], "category": "Text", "text": "公司制剂产品销售主要采用直销、传统经销和配送商三种销售模式，其中配送商模式是公司制剂产品的主要销售模式。"}, {"bbox": [268, 1066, 489, 1098], "category": "Section-header", "text": "##### 2、原料药产品销售"}, {"bbox": [216, 1103, 1272, 1174], "category": "Text", "text": "公司原料药销售主要采用自销和代理销售模式。公司原料药主要出口美洲和欧洲的制药企业，大多为长期客户。"}, {"bbox": [233, 1220, 489, 1252], "category": "Section-header", "text": "#### (2). 销售费用情况分析"}, {"bbox": [216, 1261, 424, 1292], "category": "Text", "text": "销售费用具体构成"}, {"bbox": [222, 1295, 424, 1325], "category": "Text", "text": "√适用 □不适用"}, {"bbox": [1014, 1327, 1299, 1357], "category": "Text", "text": "单位：元 币种：人民币"}, {"bbox": [217, 1359, 1299, 1539], "category": "Table", "text": "<table><thead><tr><th>具体项目名称</th><th>本期发生额</th><th>本期发生额占销售费用总额比例(%)</th></tr></thead><tbody><tr><td>职工薪酬</td><td>5,233,723.36</td><td>0.88</td></tr><tr><td>差旅费</td><td>4,349,248.51</td><td>0.74</td></tr><tr><td>市场开发费</td><td>579,951,562.90</td><td>98.03</td></tr><tr><td>其他</td><td>2,067,479.83</td><td>0.35</td></tr><tr><td>合计</td><td>591,602,014.60</td><td>100</td></tr></tbody></table>"}, {"bbox": [218, 1572, 399, 1602], "category": "Text", "text": "同行业比较情况"}, {"bbox": [222, 1605, 424, 1635], "category": "Text", "text": "√适用 □不适用"}, {"bbox": [1014, 1637, 1299, 1667], "category": "Text", "text": "单位：元 币种：人民币"}, {"bbox": [217, 1669, 1299, 1850], "category": "Table", "text": "<table><thead><tr><th>同行业可比公司</th><th>销售费用</th><th>销售费用占营业收入比例(%)</th></tr></thead><tbody><tr><td>西藏药业</td><td>1,408,962,693.24</td><td>55.15</td></tr><tr><td>润都股份</td><td>389,552,125.20</td><td>28.39</td></tr><tr><td>华纳药厂</td><td>547,311,905.68</td><td>42.34</td></tr><tr><td>昂利康</td><td>559,078,160.03</td><td>35.65</td></tr><tr><td>信立泰</td><td>1,094,427,270.13</td><td>31.43</td></tr></tbody></table>"}, {"bbox": [718, 1870, 798, 1895], "category": "Page-footer", "text": "25 / 186"}]